Novel 68Ga-PSMA-ligand Improves PET/CT Detection of Recurrent Prostate Cancer

Matthias Eiber, MD Department of Nuclear Medicine Munich, GermanMedicalResearch.com Interview with:
Matthias Eiber, MD
Department of Nuclear Medicine
Munich, Germany

Medical Research: What is the background for this study? What are the main findings?

Dr. Eiber: The background of the study is the investigation of a novel 68Ga-PSMA ligand using PET/CT in the workup of patients with recurrent prostate cancer after radical prostatectomy. Hereby, we found substantial higher detection rate compared to other methods. In total 222 (89.5%) patients showed pathological findings in 68Ga-PSMA-ligand PET/CT. Stratified by PSA-level the detection rates were 96.8%,93.0%,72.7% and 57.9% of ≥2,1-<2, 0.5-<1 and 0.2-<0.5ng/mL, respectively.

Medical Research: What should clinicians and patients take away from your report?

Dr. Eiber: For clinicians and patients the main point includes that 68Ga-PSMA PET/CT enables detection and localization of recurrent prostate cancer at a higher efficiency than reported for other tracers/imaging modalities. Most importantly, it reveals a high number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL), which in many cases can substantially influence the further clinical management.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Eiber: Further research in that area should focus on the use of 68Ga-PSMA-ligand PET imaging in the area of primary prostate cancer. Here, a direct comparison between the imaging finding and postoperative histopathology allows a better determination of the potential of this tracer as well as its usefulness in primary staging. In the setting of increased PSA-value with prior negative biopsy the use of 68Ga-PSMA PET/MR imaging combining the excellent morphological detail, multiparametric functional information in MR and molecular information in PET could possible improve the detection of primary prostate cancer

Citation:

Eiber, T. Maurer, M. Souvatzoglou, A. J. Beer, A. Ruffani, B. Haller, F.-P. Graner, H. Kubler, U. Haberhorn, M. Eisenhut, H.-J. Wester, J. E. Gschwend, M. Schwaiger. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine, 2015; 56 (5): 668 DOI: 10.2967/jnumed.115.154153

 

[wysija_form id=”1″]

MedicalResearch.com Interview with: Matthias Eiber, MD (2015). Tracer Improves PET/CT Detection of Recurrent Prostate Cancer